Ankylosing spondylitis could be treated with immune therapy
Results from a Phase III clinical trial indicate that patients suffering from ankylosing spondylitis could benefit from the biologic drug ixekizumab...
List view / Grid view
Results from a Phase III clinical trial indicate that patients suffering from ankylosing spondylitis could benefit from the biologic drug ixekizumab...
Most pharmaceutical companies are now outsourcing work to smaller firms, and here, European Pharmaceutical Review looks at current trends...
Butterworth Laboratories provides outsourced analytical chemistry services to the global pharmaceutical and related industries, specialising in raw materials analysis. It has expertise in complex wet chemistry techniques, extensive experience in residual solvent analysis, and full instrumental capability in elemental impurity analysis.
Small spectrometry chips could be the future for materials analysis systems, optical coherent tomography in medical imaging and in optical networks...
This In-Depth Focus examines methods to improve efficiency on the production line and explores a LC-MS based multi-attribute method for characterisation and QC testing of protein therapeutics.
Severe asthma sufferers could benefit from newer targeted therapies, and could be identified through levels of periostin in their airways...
The KEYNOTE-048 study examined the use of immunotherapy with pembrolizumab rather than the standard treatment using cetuximab for head and neck cancer...
A 3D bioprinting technique could, in the future, allow the creation of human tissue structures for the analysis of various diseases...
In this issue: LC-MS multi-attribute methods for the characterising and QC testing therapeutics, integrating data from Quality Control and Production to enable fast and informed decisions, and Solid-state NMR spectroscopy: using freeze drying to predict the stability of biological products.
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...
A study trialling a short course of trastuzumab in HER2 positive breast cancer patients showed that it is as effective and cheaper than a longer course...
Dr Scott Gottlieb highlighted how brand reference drug companies voluntarily withdraw their marketing applications and stopped updating their labelling...
US FDA commissioner has announced steps to modernise the drug development process to improve efficiency and promote innovation...
A report has suggested that growth of medical cannabis will reach between $11.9 and $17.1 billion by 2020, and is currently around $5 to $6 billion...
The algorithm has the potential to standardise and automate routine breast density assessment, with AI being central to breast cancer risk assessment...